clinical trial · NCT01437111
Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
Organon and Co·phase3·completed·n = 200
OsteoporosisMK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet
brief summary
This study will assess the effect of 26 weeks of once-weekly treatment with MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) on serum levels of 25-hydroxyvitamin D \[25(OH)D\].
started
Oct 26, 2011
primary completion
Dec 5, 2012
completion
Dec 5, 2012
last updated
Apr 22, 2024
official title
A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatment of Osteoporosis in Postmenopausal Women and Men
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol